

Specialty Pharmacy Program

Votrient™ (pazopanib)

DESCRIPTION

Votrient is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma.

APPROVAL DURATION

Approval duration: 1 year

APPROVAL CRITERIA

FDA-Approved Indication(s)

1. Treatment of advanced renal cell carcinoma (RCC).